Steady decline, page-44

I'm very confident that the 'Safety' component of the 'First Patient' trial was completed without any safety concerns
whatsoever. It is an ASX continuous disclosure rule that if any such concerns regarding Safety do arise the Co would
be obliged to communicate this.

Efficacy on the other hand is treated very differently, therefore, no such communication regarding its success or
otherwise is required and nor should it be as 'Efficacy' based on the results of just the One Patient is not a complete
or a fair sample of the tech performance.

As noted elsewhere previously, the definition of what constitutes a cohort does become a little grey, is it 5 or is it
15 patients? While I rate IBX as still a "Buy" frustration with the trading band of 7-8 cents for the best part of August
is taking its toll on some holders.